Overall , @ previously untreated stage II-III operable breast cancer patients were randomized to receive either standard treatment ( arm A , n = @ ) , consisting of fluorouracil , epirubicin , and cyclophosphamide ( FEC@ : @ , @ , and @ mg/m ( @ ) , respectively , for @ cycles ) followed by docetaxel ( @ mg/m ( @ ) for @ cycles ) , or adapted treatment ( arm B , n = @ ) , beginning with @ cycles of FEC@ and switching to docetaxel if tumor size decreased by < @ % after @ cycles or < @ % after @ cycles of FEC@ ( ultrasound assessments according to World Health Organization criteria ) .